Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M5JA
|
|||
| Former ID |
DIB017002
|
|||
| Drug Name |
Lumiliximab
|
|||
| Synonyms |
Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 2 | [1] | |
| Company |
IDEC Pharmaceuticals Corp; Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte IgE receptor (CD23) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| IL3 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | NOTCH2 intracellular domain regulates transcription | |||
| WikiPathways | Human Complement System | |||
| Signaling by NOTCH2 | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health. | |||
| REF 2 | Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.